Tumour suppressors hamartin and tuberin: intracellular signalling
Abstract
Tumour suppressors hamartin and tuberin, encoded by tuberous sclerosis complex 1(TSC1) and TSC2 genes, respectively, are critical regulators of cell growth and proliferation. Mutations in TSC1 and TSC2 genes are the cause of an autosomal dominant disorder known as tuberous sclerosis complex (TSC). Another genetic disorder, lymphangioleiomyomatosis (LAM), is also associated with mutations in the TSC2 gene. Hamartin and tuberin control cell growth by negatively regulating S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), potentially through their upstream modulator mammalian target of rapamycin (mTOR). Growth factors and insulin promote Akt/PKB-dependent phosphorylation of tuberin, which in turn, releases S6K1 from negative regulation by tuberin and results in the activation of S6K1. Although much has been written regarding the molecular genetics of TSC and LAM, which is associated with either the loss of or mutation in the TSC1 and TSC2 genes, few reviews have addressed the intracellular signalling pathways regulated by hamartin and tuberin. The current review will fill the gap in our understanding of their role in cellular signalling networks, and by improving this understanding, an integrated picture regarding the normal function of tuberin and hamartin is beginning to emerge.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TSC1 and TSC2 are negative regulators of mTOR phosphorylation by blocking the small GTPase Rheb activity.
“Recently, it has been demonstrated that two tumour suppressor genes, the tuberous sclerosis complex (TSC) gene TSC1 (or Hamartin) and TSC2 (or Tuberin) were negative regulators of mTOR phosphorylation [78] by blocking the small GTPase Rheb activity, which is a positive regulator of mTOR [79, 80].”
From PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease (2009) · cites this paper as [78]
p53 activation is able to inhibit the activity of mTOR through a pathway involving the subsequent activation of TSC1 and TSC2.
“Furthermore, reports showed that p53 activation is able to inhibit the activity of mTOR through a pathway involving the subsequent activation of TSC gene products TSC1 and TSC2, which are tumour suppressors and negative regulators of mTOR [78, 103–105].”
From PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease (2009) · cites this paper as [78]
Cites
Ribosomal S6 Kinase Signaling and the Control of Translation
Dufner, A., & Thomas, G. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4683 · Cited by 676 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
TSC1 Stabilizes TSC2 by Inhibiting the Interaction between TSC2 and the HERC1 Ubiquitin Ligase
Chong-Kopera, H., Inoki, K., Li, Y., Zhu, T., Garcia-Gonzalo, F. R., Rosa, J. L., & Guan, K.-L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500451200 · Cited by 234 · see citing works
Chévere-Torres, I., Kaphzan, H., Bhattacharya, A., Kang, A., Maki, J. M., Gambello, M. J., Arbiser, J. L., Santini, E., & Klann, E. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.028 · Cited by 83 · see citing works
PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease
Morel, M., Couturier, J., Lafay‐Chebassier, C., Paccalin, M., & Page, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00849.x · Cited by 47 · see citing works
- Authors
- Krymskaya, V. P.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Krymskaya, Vera P.
- ORCID
- Krymskaya, Vera P.
- Venue
- Cellular Signalling
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 15
- Issue
- 8
- Pages
- 729-739
- ISSN
- 0898-6568 (ISSN-L)
- OpenAlex
- W2038455539
- Cited by
- 130
- References
- 1
- Citations by year
- 2025: 5 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cellular Signalling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- LAM Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Physiology › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Keywords
- hamartin, tuberin, tumour suppressor, tuberous sclerosis complex, lymphangioleiomyomatosis, mTOR signaling, S6 kinase 1, 4E-BP1, Akt phosphorylation, cell growth regulation, cell proliferation, insulin signaling, growth factor signaling
- MeSH terms
- Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Animals, Humans, Mutation, Protein Kinases, Proteins, Proto-Oncogene Proteins, Repressor Proteins, Signal Transduction, Protein Serine-Threonine Kinases, Protein Structure, Tertiary, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review